ReviewPharmaceuticals (Basel, Switzerland)2019
2018 FDA Tides Harvest.
Review in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Eplontersen for the Treatment of Hereditary Transthyretin Amyloidosis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation.Current research in toxicology · 2025Article
- Porous silicon and silica carriers for delivery of peptide therapeutics.Drug delivery and translational research · 2024Review
- Peptide-Based Therapeutics in Cancer Therapy.Molecular biotechnology · 2024Review
- Biocompatible strategies for peptide macrocyclisation.Chemical science · 2024Review
- 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2024Review
- 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics.International journal of peptide research and therapeutics · 2023Review
- Greener Cleavage of Protected Peptide Fragments from Sieber Amide Resin.ChemistryOpen · 2022Article
- Strategies for Improving Peptide Stability and Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication.Frontiers in immunology · 2022Article
- Insight into purification of monoclonal antibodies in industrial columnsThe Analyst · 2021Article
- Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.Drug delivery and translational research · 2021Review
- The emerging roles of circular RNAs in regulating the fate of stem cells.Molecular and cellular biochemistry · 2021Review
- A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis.Neurology and therapy · 2020Review
- Peptide Therapeutics 2.0.Molecules (Basel, Switzerland) · 2020Article
- New Chemical Modalities and Strategic Thinking in Early Drug Discovery.ACS medicinal chemistry letters · 2020Article
- 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.Circulation research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.